Daprodustat Patent Expiration

Daprodustat is Used for managing anemia associated with chronic kidney disease. It was first introduced by Glaxosmithkline Intellectual Property No 2 Ltd England in its drug Jesduvroq on Feb 1, 2023.


Daprodustat Patents

Given below is the list of patents protecting Daprodustat, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Jesduvroq US11117871 Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof Mar 13, 2038 Glaxosmithkline
Jesduvroq US11643397 Prolyl hydroxylase inhibitors Jun 22, 2027 Glaxosmithkline
Jesduvroq US11649217 Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof Mar 13, 2038 Glaxosmithkline
Jesduvroq US8324208 Prolyl hydroxylase inhibitors Dec 11, 2028 Glaxosmithkline
Jesduvroq US8557834 Prolyl hydroxylase inhibitors Jun 22, 2027 Glaxosmithkline
Jesduvroq US8815884 Prolyl hydroxylase inhibitors Jun 22, 2027 Glaxosmithkline


Coming Soon

Patent Strength Analyzer

Let us know if you're excited!

🤩🥱

Thank you for your response 🥳